Just rolling it around in my head. When I started watching but not closely before the last read out, I remember the "average" as stated by Yahoo as about 1.7M but it did spike and as some time late it picked up and was bouncing around in a few million as you say. Nothing this high.
I do remember a large spike a week or two before the readout which crushed the price and then they gave the bad news. I'm observing that this trend is different. It seems people decided to make a much larger wager on this readout.
Could their willingness to make large bets be supported by short positions similar to what you described in another thread?
Can someone who remembers tell me what the volume was like preceding the comet-1 and comet-2?
I didn't really start watching until the last readout and I'm wondering how it compares. Looking at the charts, the volume seem quite a bit higher than before and very well sustained. Whether it's appropriate to read into it or not will be determined later.
The one that caught my attention was the phase 2 study of cabozantinib versus sunitinib in first-line RCC.
It has a chance to do better than Lenvatinib and if it does, we very well could be looking at the next first in line treatment with Cabo.
This is one to watch.
I don't get the impression that the recent run up has been due to expectations of the financials. Those that have been accumulating will likely take advantage of the downward pressure from the financials to give strong resistance.
This is exactly what I was asking. So, there is precedence. Now what are Exelixis' intentions? Wait and see if they say they're "in communication with the FDA".
What would the trial design look like for looking visceral mets compared to the original trial design?
If there is a good overlap and the data is that good, then I would expect a lot of discussion with the FDA. Is there precedence for this type of approval?
Those are my questions.
So.... Is it possible to finagle a combo therapy to show OS improvement in respect to visceral metastases?
I'm not an expert on prostate cancers but the isn't the survival rate pretty high. By removing those that don't survive, how are the visceral metastases improved? IIt seems that visceral metastases would be a high concern.
You realize you're referring to WIlder as he is the one spoofing me. I agree with NO INTELLIGENCE as he's engaged in a childs game.